ArticleLancet (London, England)2018
Atezolizumab and bladder cancer: facing a complex disease.
Article in Lancet (London, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Precision Medicine in Bladder Cancer: Present Challenges and Future Directions.Journal of personalized medicine · 2023Review
- Identification and validation of a dysregulated TME-related gene signature for predicting prognosis, and immunological properties in bladder cancer.Frontiers in immunology · 2023Article
- Allosteric activation of the metabolic enzyme GPD1 inhibits bladder cancer growth via the lysoPC-PAFR-TRPV2 axis.Journal of hematology & oncology · 2022Article
- Medical Image Diagnostic Value of Computed Tomography for Bladder Tumors.Computational and mathematical methods in medicine · 2021Article
- Development and validation of a novel stem cell subtype for bladder cancer based on stem genomic profiling.Stem cell research & therapy · 2020Article
- Chaetocin Abrogates the Self-Renewal of Bladder Cancer Stem Cells via the Suppression of the KMT1A-GATA3-STAT3 Circuit.Frontiers in cell and developmental biology · 2020Article
- The lncRNA DLX6-AS1 promoted cell proliferation, invasion, migration and epithelial-to-mesenchymal transition in bladder cancer via modulating Wnt/β-catenin signaling pathway.Cancer cell international · 2019Article
- The mechanisms of acute interstitial nephritis in the era of immune checkpoint inhibitors in melanoma.Therapeutic advances in medical oncology · 2019Review
- Hypoxia-elevated circELP3 contributes to bladder cancer progression and cisplatin resistance.International journal of biological sciences · 2019Article
- Mesenchymal glioblastoma constitutes a major ceRNA signature in the TGF-β pathway.Theranostics · 2018Article
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
29413038What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.